What this study adds’ statements:
- Increasing clinical experience may result in omission of in
vivo animal studies for certain cell-based therapies.
- Animal studies aim primarily at providing proof-of-concept and have
limited relevance for tumourigenicity evaluation.
- Available knowledge and relevance of animal studies should be
considered, when tailoring the non-clinical development program for
cell-based products.